|
Gene: ARHGAP22 |
Gene summary for ARHGAP22 |
Gene summary. |
Gene information | Species | Human | Gene symbol | ARHGAP22 | Gene ID | 58504 |
Gene name | Rho GTPase activating protein 22 | |
Gene Alias | RhoGAP2 | |
Cytomap | 10q11.22-q11.23 | |
Gene Type | protein-coding | GO ID | GO:0001525 | UniProtAcc | Q7Z5H3 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
58504 | ARHGAP22 | PTC07 | Human | Thyroid | PTC | 3.99e-08 | 1.32e-01 | 0.2044 |
58504 | ARHGAP22 | ATC11 | Human | Thyroid | ATC | 9.20e-14 | 9.95e-01 | 0.3386 |
58504 | ARHGAP22 | ATC12 | Human | Thyroid | ATC | 1.65e-14 | 3.24e-01 | 0.34 |
58504 | ARHGAP22 | ATC3 | Human | Thyroid | ATC | 5.41e-25 | 1.26e+00 | 0.338 |
58504 | ARHGAP22 | ATC4 | Human | Thyroid | ATC | 3.44e-20 | 3.92e-01 | 0.34 |
Page: 1 |
Transcriptomic changes along malignancy continuum. |
Tissue | Expression Dynamics | Abbreviation |
Thyroid | ATC: Anaplastic thyroid cancer | |
HT: Hashimoto's thyroiditis | ||
PTC: Papillary thyroid cancer |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:005105617 | Thyroid | PTC | regulation of small GTPase mediated signal transduction | 132/5968 | 302/18723 | 9.26e-06 | 1.04e-04 | 132 |
GO:004308718 | Thyroid | PTC | regulation of GTPase activity | 148/5968 | 348/18723 | 1.63e-05 | 1.71e-04 | 148 |
GO:00991738 | Thyroid | PTC | postsynapse organization | 77/5968 | 168/18723 | 1.01e-04 | 8.25e-04 | 77 |
GO:00991754 | Thyroid | PTC | regulation of postsynapse organization | 45/5968 | 90/18723 | 2.57e-04 | 1.84e-03 | 45 |
GO:004354714 | Thyroid | PTC | positive regulation of GTPase activity | 103/5968 | 255/18723 | 2.38e-03 | 1.25e-02 | 103 |
GO:00508089 | Thyroid | PTC | synapse organization | 161/5968 | 426/18723 | 5.11e-03 | 2.36e-02 | 161 |
GO:00508074 | Thyroid | PTC | regulation of synapse organization | 84/5968 | 211/18723 | 8.72e-03 | 3.64e-02 | 84 |
GO:00508032 | Thyroid | PTC | regulation of synapse structure or activity | 86/5968 | 218/18723 | 1.05e-02 | 4.23e-02 | 86 |
GO:005105618 | Thyroid | ATC | regulation of small GTPase mediated signal transduction | 141/6293 | 302/18723 | 1.43e-06 | 1.77e-05 | 141 |
GO:004308719 | Thyroid | ATC | regulation of GTPase activity | 153/6293 | 348/18723 | 3.24e-05 | 2.68e-04 | 153 |
GO:009917314 | Thyroid | ATC | postsynapse organization | 78/6293 | 168/18723 | 3.66e-04 | 2.26e-03 | 78 |
GO:009917512 | Thyroid | ATC | regulation of postsynapse organization | 44/6293 | 90/18723 | 1.89e-03 | 9.27e-03 | 44 |
GO:004354715 | Thyroid | ATC | positive regulation of GTPase activity | 106/6293 | 255/18723 | 4.58e-03 | 1.89e-02 | 106 |
GO:005080712 | Thyroid | ATC | regulation of synapse organization | 87/6293 | 211/18723 | 1.20e-02 | 4.27e-02 | 87 |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ARHGAP22 | SNV | Missense_Mutation | novel | c.1012N>C | p.Glu338Gln | p.E338Q | Q7Z5H3 | protein_coding | deleterious(0) | probably_damaging(0.937) | TCGA-H7-8502-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Chemotherapy | unknown | SD |
ARHGAP22 | SNV | Missense_Mutation | rs752411389 | c.169N>T | p.Arg57Cys | p.R57C | Q7Z5H3 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-HC-7752-01 | Prostate | prostate adenocarcinoma | Male | <65 | 7 | Unknown | Unknown | SD |
ARHGAP22 | SNV | Missense_Mutation | rs781044438 | c.361G>A | p.Glu121Lys | p.E121K | Q7Z5H3 | protein_coding | deleterious(0) | probably_damaging(0.992) | TCGA-D7-A6EY-01 | Stomach | stomach adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD |
ARHGAP22 | SNV | Missense_Mutation | rs369200749 | c.448N>A | p.Gly150Arg | p.G150R | Q7Z5H3 | protein_coding | deleterious(0.03) | benign(0.017) | TCGA-F1-6177-01 | Stomach | stomach adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
ARHGAP22 | SNV | Missense_Mutation | c.2001N>A | p.Met667Ile | p.M667I | Q7Z5H3 | protein_coding | deleterious(0) | probably_damaging(0.946) | TCGA-HF-7133-01 | Stomach | stomach adenocarcinoma | Female | Unknown | III/IV | Chemotherapy | epirubicin | SD | |
ARHGAP22 | SNV | Missense_Mutation | novel | c.145N>C | p.Ser49Arg | p.S49R | Q7Z5H3 | protein_coding | deleterious(0.01) | possibly_damaging(0.575) | TCGA-HF-A5NB-01 | Stomach | stomach adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | fluorouracil | SD |
ARHGAP22 | SNV | Missense_Mutation | novel | c.643N>A | p.Gln215Lys | p.Q215K | Q7Z5H3 | protein_coding | deleterious(0) | probably_damaging(0.968) | TCGA-HU-8238-01 | Stomach | stomach adenocarcinoma | Male | <65 | III/IV | Chemotherapy | didox | SD |
ARHGAP22 | SNV | Missense_Mutation | rs773286684 | c.1828N>T | p.Arg610Cys | p.R610C | Q7Z5H3 | protein_coding | tolerated(0.06) | benign(0.005) | TCGA-HU-8602-01 | Stomach | stomach adenocarcinoma | Female | <65 | I/II | Chemotherapy | xeloda | CR |
ARHGAP22 | SNV | Missense_Mutation | novel | c.1837G>A | p.Glu613Lys | p.E613K | Q7Z5H3 | protein_coding | tolerated(0.52) | benign(0.014) | TCGA-R5-A7ZI-01 | Stomach | stomach adenocarcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
ARHGAP22 | SNV | Missense_Mutation | rs144924707 | c.979N>A | p.Val327Ile | p.V327I | Q7Z5H3 | protein_coding | deleterious(0) | probably_damaging(0.987) | TCGA-RD-A8NB-01 | Stomach | stomach adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD |
Page: 1 2 3 4 5 6 7 8 9 10 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |